[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335325-105":59,"doc-detail-335325-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","metformin-use-and-risk-of-myeloproliferative-neoplasms-a-danish-population-based-case-control-study","Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study","","Metformin use was assessed for its association with the risk of myeloproliferative neoplasms (MPN) in a Danish population-based case-control design. MPN cases diagnosed between 2010 and 2018 were identified from Danish registers, and metformin use prior to diagnosis was determined. Ever-use and long-term use (≥5 years) were compared with age- and sex-matched controls to estimate odds ratios, including fully adjusted models. Results showed significantly lower odds of MPN with metformin, supported by a dose-response pattern and the largest effects in ET and PV subtypes, while causality could not be inferred due to the retrospective design.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metformin-use-and-risk-of-myeloproliferative-neoplasms-a-danish-population-based-case-control-study/335325/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metformin-use-and-risk-of-myeloproliferative-neoplasms-a-danish-population-based-case-control-study/335325.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main research question about metformin and MPN risk?","Question",{"text":113,"@type":114},"The study investigated whether metformin use before MPN diagnosis was associated with the risk of developing myeloproliferative neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the case-control study conducted?",{"text":118,"@type":114},"It used Danish population registers to identify MPN cases diagnosed between 2010 and 2018 and compared metformin use with an age- and sex-matched control group from the general population.",{"name":120,"@type":111,"acceptedAnswer":121},"Did metformin show a dose-response relationship?",{"text":122,"@type":114},"Yes. A dose-response pattern was observed when cumulative treatment duration was analyzed, and it remained consistent in stratified analyses by sex, age, and MPN subtypes, especially for ET and PV.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335325,1790173009,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","REGULAR ARTICLE  \nMetformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study  \nDaniel Tuyet Kristensen, 1-3,* Andreas Kiesbye Øvlisen, 1, 2,* Lasse Hjort Kyneb Jakobsen, 1 Marianne Tang Severinsen, 1, 2  \nLouise Hur Hannig,4 Jørn Starklint,5 Morten Hagemann Hilsøe,6 Anders Pommer Vallentin,7 Mette Brabrand,8 Hans Carl Hasselbalch,9 Tarec Christoffer El-Galaly, 1, 2 , 10, 11 and Anne Stidsholt Roug 1-3  \n1 Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; 2 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3 Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; 4 Department of Internal Medicine, Vejle Hospital, Vejle, Denmark; 5 Department of Internal Medicine, Section for Hematology, Regional Hospital West, Gødstrup, Denmark; 6 Department of Hematology, Hospital of Southwest Jutland, Esbjerg, Denmark; 7 Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 8 Department of Haematology, Odense University Hospital, Odense, Denmark;  \n9 Department of Hematology, Zealand University Hospital, Roskilde, Denmark; 10 Department of Haematology, Haematology Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark; and 11 Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institute, Stockholm, Sweden  \nKey Points  \n• Metformin use was associated with asigniﬁcant decrease in risk of MPN, with the largest effect observed for the ET and PV subtypes.  \n• A dose-response relationship supported the association with increasing treatment duration, in particular ≥5 years.  \nPrevious studies have suggested that metformin has beneﬁcial effects beyond its glucoselowering properties, particularly in terms of its potential as an antineoplastic and cancerpreventive agent. In this study, we aimed to investigate the association between metforminuse and the risk of myeloproliferative neoplasms (MPN) . We conducted a population-based case-control study using Danish registers. Cases with MPN diagnosed between 2010 and 2018 were identiﬁed, and metformin use before the MPN diagnosis was ascertained. We compared metformin use among cases with MPN and an age- and sex-matched control group from the Danish general population to estimate age- and sex-adjusted odds ratios (ORs) and fully adjusted ORs (aORs) for the association between metformin use and risk of MPN. The study population included 3816 cases and 19 080 controls. Overall, 7.0% of cases and 8.2% of controls were categorized as ever-users of metformin, resulting in an OR for MPN of 0 .84 (95% conﬁdence interval [CI], 0 .73-0.96) and an aOR of 0 .70 (95% CI, 0 .61-0.81) . Long-term metformin use (≥5 years) was more infrequent and comprised 1.1% of cases and 2.0% of controls, resulting in an OR of 0.57 (95% CI, 0.42-0.79) and an aOR of 0.45 (95% CI, 0.33-0.63) . A dose-response relationship was observed when cumulative duration of treatment was analyzed, and this was consistent in stratiﬁed analyses of sex, age, and MPN subtypes. In conclusion, metformin use was associated with signiﬁcantly lower odds of an MPN diagnosis, indicating its potential cancer-preventive effect. Given the retrospective design, causality cannot be inferred.  \nSubmitted 5 December 2023; accepted 11 April 2024; prepublished online on Blood Advances First Edition 17 May 2024; final version published online 27 August 2024 . [https://doi.org/10.1182/bloodadvances.2023012266](https://doi.org/10.1182/bloodadvances.2023012266) .  \n*D.T.K. and A.K.Ø . contributed equally to this study.  \nPer Danish law, the data cannot be shared directly; however, they can be accessed through application.  \nAdditional information is available on request from the corresponding author, Anne Stidsholt Roug ([annrou@rm.dk](annrou@rm.dk)) or [at](at www.rkkp.dk/in-english/ and)[ www.rkkp.dk/in-en","cbCaipHdrBnrnvIz","https://ap.wps.com/l/cbCaipHdrBnrnvIz","pdf",628666,"English","# Key Points\n# Introduction\n## Background on MPN\n## Metformin and prior evidence\n# Study Design and Methods\n## Danish register-based case-control approach\n## Study population and matching\n# Results\n## Ever-use vs controls\n## Long-term use (≥5 years)\n## Dose-response and subgroup consistency\n# Conclusion and Interpretation\n## Main findings\n## Limitations on causality","[{\"question\":\"What was the main research question about metformin and MPN risk?\",\"answer\":\"The study investigated whether metformin use before MPN diagnosis was associated with the risk of developing myeloproliferative neoplasms.\"},{\"question\":\"How was the case-control study conducted?\",\"answer\":\"It used Danish population registers to identify MPN cases diagnosed between 2010 and 2018 and compared metformin use with an age- and sex-matched control group from the general population.\"},{\"question\":\"Did metformin show a dose-response relationship?\",\"answer\":\"Yes. A dose-response pattern was observed when cumulative treatment duration was analyzed, and it remained consistent in stratified analyses by sex, age, and MPN subtypes, especially for ET and PV.\"}]","Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study | PDF",1790010541]